Glancy Prongay & Murray LLP (“GPM”) announces an investigation on behalf of SteadyMed Ltd. (“SteadyMed” or the “Company”) (NASDAQ:STDY) investors concerning the Company and its officers’ possible violations of federal securities laws. To obtain information or aid in the investigation, please visit the SteadyMed investigation page on our website at www.glancylaw.com/case/steadymed-ltd

On August 31, 2017, SteadyMed announced that it received a Refusal to File letter from the FDA in connection with its New Drug Application (“NDA”) for Treyvent, a pulmonary arterial hypertension treatment. Based on a preliminary review of the NDA, which was submitted in June of 2017, the FDA determined that the application is not sufficiently complete to permit a substantive review.

On this news, SteadyMed's share price fell 33% on August 31, 2017, thereby injuring investors.

If you purchased SteadyMed securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to shareholders@glancylaw.com, or visit our website at www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.